The Diagnostic Imaging MRI modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of MRI across the healthcare continuum, including breast, neurological, cardiovascular, prostate imaging, and more.
September 10th 2025
For HER2-positive breast cancer patients with radiologic complete response on breast MRI after neoadjuvant chemotherapy (NAC), the absence of calcifications was associated with over a 13 percent higher positive predictive value (PPV) for pathologic complete response (pCR).
September 2nd 2025
Can Multimodal AI Enhance Prediction of Biochemical Recurrence After Prostatectomy?
August 8th 2025A deep learning multimodal model that incorporates MRI features offered nearly double the sensitivity for predicting post-prostatectomy biochemical recurrence of prostate cancer in comparison to the traditional CAPRA-S scoring system.
Large Medicare Study Shows Black Men Less Likely to Receive PET and MRI for Prostate Cancer Imaging
July 31st 2025An analysis of over 749,000 Medicare beneficiaries diagnosed with prostate cancer over a five-year period found that Black men were 13 percent less likely to receive PET imaging and 16 percent less likely to receive MRI in comparison to White men.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
July 22nd 2025In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.
Stroke MRI Study Assesses Impact of Motion Artifacts Upon AI and Radiologist Lesion Detection
July 16th 2025Noting a 7.4 percent incidence of motion artifacts on brain MRI scans for suspected stroke patients, the authors of a new study found that motion artifacts can reduce radiologist and AI accuracy for detecting hemorrhagic lesions.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.